Previous studies have shown frequent allelic loss on chromosome 13 in esophageal squamous cell carcinoma (ESCC). We assessed the frequency of allelic loss on chromosome 13q14 and mutations of deleted in cancer 1 (DICE1) (also found on 13q14) in ESCC patients to determine if this candidate tumor suppressor gene has a role in the development of ESCC, and whether this gene was an inactivation target for allelic loss on chromosome 13q14. Initially, we examined allelic loss at five markers flanking DICE1 in 56 ESCC patients from Shanxi Province, China, and then examined the entire coding sequence of this gene for mutations using polymerase chain reaction-single-strand confirmation polymorphism (PCR-SSCP) analysis and DNA sequencing. Subsequently, we extended our evaluation to an additional 80 ESCC patients and 232 healthy individuals to confirm the germline variant found in the initial 56 ESCC patients. The frequencies of allelic loss were 71, 58, and 75% for D13S325, D13S757, and D13S887, respectively, in the initial 56 ESCC patients studied. Overall, 73% of informative patients had loss of heterozygosity (LOH) for at least one of these three markers. Somatic mutations were identified in three patients (3/56, 5%), and one novel polymorphism was identified in 3% of ESCC patients (4/ 136) and 3% of healthy individuals (6/232). We conclude that DICE1 mutations occur in ESCC but are infrequent. The candidate tumor suppressor gene corresponding to the frequent allelic loss on chromosome 13q14 in ESCC remains unknown.
Introduction
Esophageal squamous cell carcinoma (ESCC) is very common in many areas of China, especially in Shanxi Province (Hu et al., 1992) . In previous studies in Shanxi Province, we found frequent loss of heterozygosity (LOH) on chromosome 13q (Hu et al., 1999 . Although LOH on chromosome 13q is frequently detected in many types of tumors (Kuroki et al., 1995; Montesano et al., 1996; Eı`rı`ksdottir et al., 1998; Hyytinen et al., 1999) , only two tumor suppressor genes have been identified on this chromosome to date, RB1 (13q14) and BRCA2 (13q12) (Lee et al., 1987; MacGee et al., 1989; Wooster et al., 1995) . LOH at the RB1 locus has been reported in 54% of ESCCs (Boynton et al., 1991; Huang et al., 1992) , but few mutations have been detected (Maesawa et al., 1994) . We reported frequent allelic loss on chromosome 13q12 in ESCC patients, but infrequent detection of mutations in BRCA2 (Hu et al., 2002) . All these studies suggest that other as yet unknown gene(s) on chromosome 13q may be involved in the pathogenesis of ESCC. A candidate tumor suppressor gene, deleted in cancer 1 (DICE1) (GenBank database Accession AF097645) was recently isolated and localized to chromosome 13q14.12-q14.2 (Wieland et al., 1999) . DICE1 has 887 amino acids, is highly conserved in evolution, and its mRNA is expressed in a wide variety of fetal and adult tissues. DICE1 corresponds to an evolutionarily highly conserved protein of 100 kDa suggesting an important cellular function (Wieland et al., 1999) . In addition, DICE1 showed loss or downregulation of expression in most nonsmall cell lung carcinomas tested (Wieland et al., 1999) . Although DICE1 is located in a critical region where LOH is commonly observed in many types of human cancers, it has not yet been studied in many human cancers, including esophageal cancer.
In the present study, we examined LOH on chromosome 13q14 using five markers flanking DICE1 in ESCC patients from Shanxi, China, and then tested for mutations in this gene using single-strand confirmation polymorphism (SSCP) analysis and DNA sequencing in the same group of patients.
Results

Allelic loss in ESCC patients
We found that all 56 ESCC patients we initially tested were homozygous for markers D13S1203 and D13S1161. For the remaining three markers, D13S325, D13S757, and D13S887, the frequencies of LOH were 71% (24 of 34 informative cases), 58% (15 of 26 informative cases), and 75% (nine of 12 informative cases), respectively. Overall, 73% (34 of 44 cases informative at one or more of these three markers) had LOH for at least one marker.
Alterations of DICE1 in ESCC patients
Screening the entire coding region of DICE1 in tumor and blood DNA of 56 ESCC patients identified somatic mutations in three patients (3/56, 5%) and a 3 bp intronic germline deletion in two cases. These alterations are listed in Table 1 and examples are shown in Figures 1 and 2 . Demographic and clinical/pathological characteristics as well as selected cancer lifestyle risk factors for these five patients with a DICE1 alteration are listed in Table 1 . We found evidence for potential biallelic alteration of DICE1 in just one of 56 ESCC (2%) cases (Table 1) . This case (#480) had a missense mutation on one allele and lost the wild-type allele in tumor.
A novel polymorphism in Chinese
To evaluate whether the germline variant (6033-6035del CTT) was a specific germline mutation in ESCC or a novel polymorphism in Chinese, we examined an additional set of ESCC patients as well as healthy individuals. The germline variant was observed in two of 80 additional ESCC patients, five of 101 healthy individuals from Beijing, and one of 131 healthy individuals from Yangcheng. The overall variant frequencies were 3% (4/136) in ESCC patients and 3% in healthy individuals (6/232).
Genetic alterations of DICE1 and LOH on 13q14
The number of cases with a DICE1 mutation was too small for meaningful comparison with LOH at 13q14. Of 34 informative cases at D13S325, two (2/24, 8%) had a mutation in DICE1; one of 15 (7%) informative cases at D13S757 had a mutation; and none of 12 informative cases at D13S887 had a mutation in this gene.
Discussion
Mutation in DICE1 has been previously studied only in nonsmall cell lung cancer, where Wieland et al. reported loss or downregulation of expression (Wieland et al., 1999) . Ours is the first study of DICE1 in esophageal cancer and the first to identify germline or somatic alterations in DICE1 in any cancer. We found three ESCC patients (5%) with DICE1 mutations. In addition, two of the initial 56 ESCC patients we tested had the same germline variant (6033-6035delCTT). To determine whether this variant was a specific germline mutation of DICE1 or a novel polymorphism in Chinese, we tested more ESCC patients as well as healthy individuals from Beijing (a low-risk area for ESCC) and Yangcheng County (a high-risk area for ESCC), and found a frequency of 3% in both ESCC and healthy individuals, suggesting that this germline variant is a novel polymorphism in the Chinese population. Among the cases evaluated, only one (#480) showed evidence for potential biallelic alterations in DICE1. This patient had a missense mutation at codon 431, part of the most conserved region (codon 114-444) of DICE1 gene product (Wieland et al., 1999) , and lost the wild-type allele. We do not know, however, if function was altered in this case. Our result indicated only that mutation of DICE1 is an infrequent event. Epigenetic events affecting transcription, however, may occur and remain to be evaluated (Wieland et al., 2001) . While allelic loss on 13q14 was observed frequently in our patients, most of the patients who had LOH in this region did not have a mutation in DICE1. Of the five cases who had a mutation in this gene, two had LOH, two were homozygous for all three markers flanking this gene, and one showed retention at one marker and homozygosity at the other two markers. The modest number of ESCC cases evaluated here does not permit definitive conclusions regarding the role of mutations in DICE1 and LOH on 13q14; however, DICE1 does not appear to be the target gene affected by LOH on chromosome 13q14. Thus, the gene corresponding to the frequent allelic loss on chromosome 13q14 remains unknown. 
Materials and methods
Patient selection
Patients presenting in 1995 and 1996 to the Shanxi Cancer Hospital in Taiyuan, Shanxi Province, China, who were diagnosed with ESCC and considered candidates for curative surgical resection, were identified and recruited to participate in this study. This research study was approved by the Institutional Review Boards of the Shanxi Cancer Hospital and the US National Cancer Institute (NCI). A total of 56 patients with ESCC who had a histologic diagnosis of ESCC confirmed by pathologists at both the Shanxi Cancer Hospital and the NCI were selected. None of the patients had prior therapy, and Shanxi was the ancestral home for all. After obtaining informed consent, patients were interviewed to obtain information on demographic and cancer lifestyle risk factors, and a detailed family history of cancer. A total of 56 ESCC patients, including 34 males and 22 females, were evaluated. Details on these patients have been previously reported (Huang et al., 2000) .
An additional second set of 80 ESCC patients from the Shanxi Cancer Hospital (who presented in the same manner as the 56 cases described above) and 232 healthy individuals from blood banks (101 from Beijing and 131 from Yangcheng, Shanxi Province) were examined for a germline variant that was found during the examination of the initial 56 ESCC patients in the present study.
Biologic specimen collection and processing
Venous blood (10 ml) was taken from each patient prior to surgery. Blood from healthy individuals was collected from blood banks in Beijing and Yangcheng, China. Genomic DNA was extracted and purified. Tumor tissue obtained during surgery was fixed in ethanol and embedded in paraffin.
Laser microdissection and extraction of DNA Tumor cells were microdissected under light microscopic visualization using methods previously described (EmmertBuck et al. 1996; Huang et al., 2000) .
Markers, polymerase chain reaction (PCR), and LOH reading and interpretation
Five microsatellite markers, D13S325 (13q14.11), D13S1203 (13q14.12), D13S757 (13q14.2), D13S887 (13q14.2), and D13S1161 (13q14.2), were selected (Human MapPairst Research Genetics, Huntsville, AL, USA). The total distance from D13S325 to D13S1161 is estimated at 8 Mb (http:// cedar.genetics.soton.ac.uk/public_html/read.html). DICE1 is located between D13S1203 and D13S1757. DNA extracted from tumor cells was microdissected from resection specimens, and genomic DNA extracted from venous blood was used for each patient. PCR reactions were carried out as previously reported (Huang et al., 2000) . LOH was defined as either complete or nearly complete loss of a band in the tumor sample relative to the corresponding normal DNA.
PCR, SSCP analysis, and DNA sequencing
Mutations in all 13 coding exons of DICE1 were screened by PCR-SSCP. The 14 pairs of PCR primers used to cover all intron/exon boundaries are listed in Table 2 . Tumor and normal DNA were used for each patient. PCR reactions, SSCP analyses, and DNA sequencing were conducted using methods previously described . The annealing temperatures for each PCR reaction are listed in Table 2 . All SSCP gels with band shifts were repeated and are reported as positive only when the shifts were confirmed.
Abbreviation:
ESCC, esophageal squamous cell carcinoma; SSCP, singlestrand confirmation polymorphism; PCR, polymerase chain reaction; LOH, loss of heterozygosity. 
